Winger, don't forget that Dr. Anderson (yes, the s
Post# of 36568
(Total Views: 280)
Posted On: 12/04/2019 10:50:44 AM
Winger, don't forget that Dr. Anderson (yes, the same Dr. Anderson) has reformulated Oralyn to a 2-3 puff dosage. The molecules have already been determined to be too large to enter the lungs. With Altucell Generex now has the potential to develop treatments for Type I and Type II diabetes.
Of course, the trials will cost money, but the Arizona HMO, or whatever it is called, has 25000 potential patients who may participate in the trials. Generex is a long distance from making money, but the outlines of a business plan are there.
If I am seeing the big picture correctly, the next catalyst will be the S1 announcement. MMPJoe states this will be a $40M loan that will remove the "going concern" status and move Generex one step closer to uplisting. We need to pay attention to the terms of the loan and how the money will be used. We also need to get back to $2 per share and stay there or a minimum of 5 days in order to uplist.
What we investors can't ignore is that Generex is a micro-cap biotech company listed on OTC. Last week we were informed of additional setbacks. There are reasons that stocks sell for .60 a share. Those reasons have to be addressed. Unfortunately, Generex is in tenuous risk-reward status. At $3 per share that was a distant concern. At this level it is much more serious. rj's earlier post is right on. Due diligence has to be improved. I don't think Generex can afford to waste time, money, or the goodwill of investors. "It is what it is".
Of course, the trials will cost money, but the Arizona HMO, or whatever it is called, has 25000 potential patients who may participate in the trials. Generex is a long distance from making money, but the outlines of a business plan are there.
If I am seeing the big picture correctly, the next catalyst will be the S1 announcement. MMPJoe states this will be a $40M loan that will remove the "going concern" status and move Generex one step closer to uplisting. We need to pay attention to the terms of the loan and how the money will be used. We also need to get back to $2 per share and stay there or a minimum of 5 days in order to uplist.
What we investors can't ignore is that Generex is a micro-cap biotech company listed on OTC. Last week we were informed of additional setbacks. There are reasons that stocks sell for .60 a share. Those reasons have to be addressed. Unfortunately, Generex is in tenuous risk-reward status. At $3 per share that was a distant concern. At this level it is much more serious. rj's earlier post is right on. Due diligence has to be improved. I don't think Generex can afford to waste time, money, or the goodwill of investors. "It is what it is".
(2)
(0)